<!DOCTYPE html>
<html lang="en">

<head>
  <meta charset="UTF-8" />
  <title>Konstellate</title>
  <meta name="viewport" content="width=device-width,initial-scale=1" />
  <meta name="description" content="" />
  <link href="https://cdn.jsdelivr.net/npm/modern-normalize@v2.0.0/modern-normalize.min.css" rel="stylesheet">
  <link href="https://cdn.jsdelivr.net/npm/bootstrap@5.3.2/dist/css/bootstrap.min.css" rel="stylesheet"
    crossorigin="anonymous">
  <link href="https://cdn.jsdelivr.net/npm/bootstrap-icons@1.5.0/font/bootstrap-icons.css" rel="stylesheet"
    crossorigin="anonymous">
  <link rel="icon" type="image/png" sizes="32x32" href="./assets/images/logo.png">
  <link rel="icon" type="image/png" sizes="16x16" href="./assets/images/logo.png">
  <link rel="apple-touch-icon" type="image/png" sizes="180x180" href="logo.png">
  <link rel="icon" type="image/svg+xml" href="./assets/images/logo.svg">
  <meta name="theme-color" content="">
  <link rel="manifest" href="manifest.webmanifest">
  <link rel="preconnect" href="https://fonts.googleapis.com">
  <link rel="preconnect" href="https://fonts.gstatic.com" crossorigin>
  <link
    href="https://fonts.googleapis.com/css2?family=DM+Sans:ital,opsz,wght@0,9..40,100..1000;1,9..40,100..1000&family=Roboto:ital,wght@0,100;0,300;0,400;0,500;0,700;0,900;1,100;1,300;1,400;1,500;1,700;1,900&display=swap"
    rel="stylesheet">
  <link rel="stylesheet" type="text/css" href="./assets/css/index.css" />
</head>

<body>
  <header>
    <div class="top__navbar position-fixed">
      <p class="m-0">Konstellate | KOL Intelligence Search Engine</p>
    </div>
  </header>
  <div class="d-flex">
    <aside class="sidenav__wrapper position-fixed d-flex">
      <div>
        <div class="d-flex justify-content-center">
          <a href="#"><img src="./assets/images/logo-black.png" width="40" height="40" /></a>
        </div>
        <div class="sidenav__menu">
          <!-- <a href="result.html">
            <div class="sidenav__menu__icon">
              <img src="./assets/images/search.svg" />
            </div>
            <p>Search</p>
          </a> -->
          <a href="index.html" class="active">
            <div class="sidenav__menu__icon">
              <img src="./assets/images/dashboard.svg" />
            </div>
            <p>Dashboard</p>
          </a>
          <!-- <a href="notebook.html">
            <div class="sidenav__menu__icon">
              <img src="./assets/images/notebook.svg" />
            </div>
            <p>Notebook</p>
          </a> -->
          <!-- <a href="integration.html">
            <div class="sidenav__menu__icon">
              <img src="./assets/images/integration.svg" />
            </div>
            <p>Integration</p>
          </a> -->
        </div>
      </div>
      <div class="sidenav__user">
        <div class="sidenav__user__info">
          <span>DN</span>
        </div>
        <div class="sidenav__user__status">
          <span class="active"></span>
        </div>
      </div>
    </aside>
    <div class="page__content">
      <div class="header__wrapper">
        <div class="header__topbar d-flex">
          <div class="header__search__wrapper d-flex">
            <div class="header__search__item">
              <div class="header__search__icon">
                <i class="bi bi-bounding-box-circles"></i>
              </div>
              <input type="text" id="default-search" placeholder="Search for KOL’s" />
              <div class="header__search__right">
                <span>Watchlists</span>
                <i class="bi bi-bounding-box-circles"></i>
              </div>
            </div>
            <div class="header__search__item">
              <div class="header__search__icon">
                <i class="bi bi-bounding-box-circles"></i>
              </div>
              <input type="text" id="default-search" placeholder="Search for Events" />
              <div class="header__search__right">
                <span>Watchlists</span>
                <i class="bi bi-bounding-box-circles"></i>
              </div>
            </div>
            <button class="button">Search</button>
          </div>
          <!-- <div class="header__topbar__action d-flex align-items-center">
            <button class="button button--secondary"><img class="mr-1"
                src="./assets/images/integration.svg" />Integration</button>
            <button class="button button--secondary"><img class="mr-1" src="./assets/images/live.svg" />Live
              Help</button>
          </div> -->
        </div>
        <div class="header__filters">
          <div class="header__filters__item">
            <div class="chip__item">
              <img src="./assets/images/plus.svg" />
              Sources
            </div>
            <!-- <div class="chip__item">
              <img src="./assets/images/plus.svg" />
              Company Docs
            </div>
            <div class="chip__item">
              <img src="./assets/images/plus.svg" />
              News
            </div>
            <div class="chip__item">
              <img src="./assets/images/plus.svg" />
              Integration & Notes
            </div>
            <a href="#" class="header__filters__more">More Sources</a>
          </div>
          <div class="header__filters__item">
            <div class="select__dropdown">
              <button href="#" role="button" data-value="" class="select__dropdown__button"><span>My Content</span>
                <i class="bi bi-chevron-down"></i>
              </button>
              <ul class="select__dropdown__list">
                <li data-value="1" class="select__dropdown__list-item">Item 1</li>
                <li data-value="2" class="select__dropdown__list-item">Item 2</li>
                <li data-value="3" class="select__dropdown__list-item">Item 3</li>
                <li data-value="4" class="select__dropdown__list-item">Item 4</li>
              </ul>
            </div>
            <div class="select__dropdown ms-2">
              <button href="#" role="button" data-value="" class="select__dropdown__button"><span>Any Tag</span>
                <i class="bi bi-chevron-down"></i>
              </button>
              <ul class="select__dropdown__list">
                <li data-value="1" class="select__dropdown__list-item">Item 1</li>
                <li data-value="2" class="select__dropdown__list-item">Item 2</li>
                <li data-value="3" class="select__dropdown__list-item">Item 3</li>
                <li data-value="4" class="select__dropdown__list-item">Item 4</li>
              </ul>
            </div>
          </div> -->
          </div>
        </div>
        <main>
          <div class="page__content__wrapper d-flex">
            <div class="dashboard__sidebar">
              <div class="dashboard__sidebar__header d-flex align-items-center justify-content-between cursor-pointer">
                <h4 class="m-0">My Dashboard</h4>
                <i class="bi bi-chevron-down"></i>
              </div>
              <div class="dashboard__sidebar__item">
                <div class="dashboard__sidebar__title user_name_menu" data-id="mykol">
                  <img src="./assets/images/home.svg" />
                  My Kols
                </div>
                <div class="dashboard__sidebar__list px-2">
                 
                </div>
                <button class="button" id="load_more_List_kol_user">Load More...</button>
              </div>
            </div>
            <div class="dashboard__content" id="mykol">
              <div class="card__box">
                <div class="card__box__header d-flex align-items-center">
                  <div class="card__box__title d-flex align-items-center">
                    <img src="./assets/images/logo-black.png" />
                    <h2 class="mx-1">KOL's</h2>
                  </div>
                  <div class="card__box__menu position-relative">
                    <button class="button">
                      <i class="bi bi-three-dots"></i>
                    </button>
                    <ul class="card__box__menu__items">
                      <li data-value="1">Menu 1</li>
                      <li data-value="2">Menu 2</li>
                      <li data-value="3">Menu 3</li>
                    </ul>
                  </div>
                </div>
                <div class="card__box__content">
                  <div class="dashboard__table__wrapper position-relative px-8">
                    <button class="dashboard__table__sort">
                      Company <img src="./assets/images/sort-arrow.svg" />
                    </button>
                    <div class="dashboard__table__accordion">
                      <!-- <img src="./assets/images/arrow-down-grey.svg" class="position-absolute left-0" /> -->
                      <button><i class="bi bi-chevron-down"></i></button>
                      My KOL's
                    </div>
                    <div class="dashboard__table__content">
                      <table id="kol_table">
                        <thead>
                          <th>First Name</th>
                          <th>Last Name</th>
                          <th>Institution</th>
                        </thead>
                        <tbody></tbody>
                      </table>
                      <button class="button load__more" id="table_kol_load_more">
                        Load More...
                      </button>
                    </div>
                  </div>
                </div>
              </div>
              <div class="card__box">
                <div class="card__box__header d-flex align-items-center">
                  <div class="card__box__title d-flex align-items-center">
                    <img src="./assets/images/logo-black.png" />
                    <h2 class="mx-1">Trending KOL Topics</h2>
                  </div>
                  <div class="card__box__menu position-relative">
                    <button class="button">
                      <i class="bi bi-three-dots"></i>
                    </button>
                    <ul class="card__box__menu__items">
                      <li>Menu 1</li>
                      <li>Menu 2</li>
                      <li>Menu 3</li>
                    </ul>
                  </div>
                </div>
                <div class="card__box__content">
                  <div class="dashboard__topics__wrapper">
                    <table>
                      <colgroup>
                        <col span="1" style="width: 80%" />
                        <col span="1" style="width: 10%" />
                        <col span="1" style="width: 10%" />
                      </colgroup>
                      <thead>
                        <th>Topic</th>
                        <th>Trend (12M)</th>
                        <th>Mentions (12M)</th>
                      </thead>
                      <tbody>
                        <tr>
                          <td>
                            <span>1</span> Fezolinetant
                          </td>
                          <td>
                            <div class="topics-container">
                              <div class="topic__chart"></div>
                            </div>
                          </td>
                          <td class="dashboard__topics__chart">
                            <span>90</span>
                            <div class="chart-container">
                              <div class="topic__redial__chart"></div>
                            </div>
                          </td>
                        </tr>
                        <tr>
                          <td>
                            <span>2</span> VEOZAH
                          </td>
                          <td>
                            <div class="topics-container">
                              <div class="topic__chart"></div>
                            </div>
                          </td>
                          <td class="dashboard__topics__chart">
                            <span>90</span>
                            <div class="chart-container">
                              <div class="topic__redial__chart"></div>
                            </div>
                          </td>
                        </tr>
                        <tr>
                          <td>
                            <span>3</span> VEOZAH
                          </td>
                          <td>
                            <div class="topics-container">
                              <div class="topic__chart"></div>
                            </div>
                          </td>
                          <td class="dashboard__topics__chart">
                            <span>70</span>
                            <div class="chart-container">
                              <div class="topic__redial__chart"></div>
                            </div>
                          </td>
                        </tr>
                        <tr>
                          <td>
                            <span>4</span> VEOZAH
                          </td>
                          <td>
                            <div class="topics-container">
                              <div class="topic__chart"></div>
                            </div>
                          </td>
                          <td class="dashboard__topics__chart">
                            <span>50</span>
                            <div class="chart-container">
                              <div class="topic__redial__chart"></div>
                            </div>
                          </td>
                        </tr>
                        <tr>
                          <td>
                            <span>2</span> VEOZAH
                          </td>
                          <td>
                            <div class="topics-container">
                              <div class="topic__chart"></div>
                            </div>
                          </td>
                          <td class="dashboard__topics__chart">
                            <span>90</span>
                            <div class="chart-container">
                              <div class="topic__redial__chart"></div>
                            </div>
                          </td>
                        </tr>
                        <tr>
                          <td>
                            <span>2</span> VEOZAH
                          </td>
                          <td>
                            <div class="topics-container">
                              <div class="topic__chart"></div>
                            </div>
                          </td>
                          <td class="dashboard__topics__chart">
                            <span>90</span>
                            <div class="chart-container">
                              <div class="topic__redial__chart"></div>
                            </div>
                          </td>
                        </tr>
                        <tr>
                          <td>
                            <span>2</span> VEOZAH
                          </td>
                          <td>
                            <div class="topics-container">
                              <div class="topic__chart"></div>
                            </div>
                          </td>
                          <td class="dashboard__topics__chart">
                            <span>90</span>
                            <div class="chart-container">
                              <div class="topic__redial__chart"></div>
                            </div>
                          </td>
                        </tr>
                        <tr>
                          <td>
                            <span>2</span> VEOZAH
                          </td>
                          <td>
                            <div class="topics-container">
                              <div class="topic__chart"></div>
                            </div>
                          </td>
                          <td class="dashboard__topics__chart">
                            <span>90</span>
                            <div class="chart-container">
                              <div class="topic__redial__chart"></div>
                            </div>
                          </td>
                        </tr>
                        <tr>
                          <td>
                            <span>2</span> VEOZAH
                          </td>
                          <td>
                            <div class="topics-container">
                              <div class="topic__chart"></div>
                            </div>
                          </td>
                          <td class="dashboard__topics__chart">
                            <span>90</span>
                            <div class="chart-container">
                              <div class="topic__redial__chart"></div>
                            </div>
                          </td>
                        </tr>
                        <tr>
                          <td>
                            <span>2</span> VEOZAH
                          </td>
                          <td>
                            <div class="topics-container">
                              <div class="topic__chart"></div>
                            </div>
                          </td>
                          <td class="dashboard__topics__chart">
                            <span>90</span>
                            <div class="chart-container">
                              <div class="topic__redial__chart"></div>
                            </div>
                          </td>
                        </tr>
                      </tbody>
                    </table>
                  </div>
                </div>
              </div>
              <div class="card__box">
                <div class="card__box__header d-flex align-items-center">
                  <div class="card__box__title d-flex align-items-center">
                    <img src="./assets/images/logo-black.png" />
                    <h2 class="mx-1">KOL Analytics</h2>
                  </div>
                  <div class="card__box__menu position-relative">
                    <button class="button" onClick={handleShowDropdown}>
                      <i class="bi bi-three-dots"></i>
                    </button>
                    <ul class="card__box__menu__items">
                      <li>Menu 1</li>
                      <li>Menu 2</li>
                      <li>Menu 3</li>
                    </ul>
                  </div>
                </div>
                <div class="card__box__content">
                  <div class="dashboard__events__wrapper">
                    <div class="dashboard__events__item">
                      <div class="dashboard__events__title">
                        <img src="./assets/images/logo-blue.svg" />
                        <h4 class="m-0">Quick Note - Astellas Pharma (4503 JP) (Buy) - CFO meeting: Gro...</h4>
                        <p>Kol Name • How many Video • Total hour of video</p>
                      </div>
                      <div class="dashboard__events__count">
                        <div>19 Now</div>
                      </div>
                    </div>
                    <div class="dashboard__events__item">
                      <div class="dashboard__events__title">
                        <img src="./assets/images/logo-blue.svg" />
                        <h4 class="m-0">Quick Note - Astellas Pharma (4503 JP) (Buy) - CFO meeting: Gro...</h4>
                        <p>Kol Name • How many Video • Total hour of video</p>
                      </div>
                      <div class="dashboard__events__count">
                        <div>19 Now</div>
                        <span>AMR</span>
                      </div>
                    </div>
                    <div class="dashboard__events__item">
                      <div class="dashboard__events__title">
                        <img src="./assets/images/logo-blue.svg" />
                        <h4 class="m-0">Quick Note - Astellas Pharma (4503 JP) (Buy) - CFO meeting: Gro...</h4>
                        <p>Kol Name • How many Video • Total hour of video</p>
                      </div>
                      <div class="dashboard__events__count">
                        <div>19 Now</div>
                        <span>AMR</span>
                      </div>
                    </div>
                    <div class="dashboard__events__item">
                      <div class="dashboard__events__title">
                        <img src="./assets/images/logo-blue.svg" />
                        <h4 class="m-0">Quick Note - Astellas Pharma (4503 JP) (Buy) - CFO meeting: Gro...</h4>
                        <p>Kol Name • How many Video • Total hour of video</p>
                      </div>
                      <div class="dashboard__events__count">
                        <div>19 Now</div>
                      </div>
                    </div>
                    <div class="dashboard__events__item">
                      <div class="dashboard__events__title">
                        <img src="./assets/images/logo-blue.svg" />
                        <h4 class="m-0">Quick Note - Astellas Pharma (4503 JP) (Buy) - CFO meeting: Gro...</h4>
                        <p>Kol Name • How many Video • Total hour of video</p>
                      </div>
                      <div class="dashboard__events__count">
                        <div>19 Now</div>
                        <span>AMR</span>
                      </div>
                    </div>
                  </div>
                </div>
              </div>

            </div>
            <div class="user_selected  " id="user_name">
              <div class="d-flex page__content__wrapper result__page">
                <div class="result__sidebar">
                  <!-- <div class="result__sidebar__title result__sidebar__item">
                    <h3 class="m-0">KOL Name - Institution</h3>
                  </div> -->
                  <div class="result__sidebar__list">
                    <div class="result__sidebar__item d-flex" data-id="summary">
                      <h3 class="m-0 p-2">KOL Name - Institution</h3>
                      <!-- <div class="result__sidebar__item--content">
                        <div class="result__sidebar__item--title">
                          <h3>title</h3>
                          <ul>
                            <li>channel source</li>
                            <li> description</li>
                          </ul>
                        </div>
                        <div class="result__sidebar__item--info d-flex flex-column align-items-end">
                          <span class="result__sidebar__item--date">
                            01 Nov 2023
                          </span>
                          <div class="result__sidebar__item--action">
                            <p class="m-0">Sent-28</p>
                            <i class="bi bi-arrow-right-short"></i>
                          </div>
                        </div>
                      </div> -->
                    </div>
                    <div class="result__sidebar__item d-flex" data-id="video1">
                      <!-- <div class="result__sidebar__item--img">
                        <img class="result__sidebar__item--photo" src="./assets/images/video1.png" />
                        <button><img src="./assets/images/play-circle.svg" /></button>
                        
                      </div> -->

                      <iframe width="125px" height="90px" src="https://www.youtube.com/embed/D5XNacL1_fM"
                        frameborder="0" allowfullscreen></iframe>
                      <div class="result__sidebar__item--content">
                        <div class="result__sidebar__item--title">
                          <h3>Uromiogs Live 2023: Dr. Petros Grivas on Promising Future Treatments in Bladder Cancer
                          </h3>
                          <ul>
                            <li>GU Oncology Now</li>
                            <!-- <li> description</li> -->
                          </ul>
                        </div>
                        <div class="result__sidebar__item--info d-flex flex-column align-items-end">
                          <span class="result__sidebar__item--date">
                            Nov 9, 2023
                          </span>
                          <div class="result__sidebar__item--action">
                            <p class="m-0">Length-3:36</p>
                            <i class="bi bi-arrow-right-short"></i>
                          </div>
                        </div>
                      </div>
                    </div>
                    <div class="result__sidebar__item d-flex" data-id="video2">
                      <!-- <div class="result__sidebar__item--img">
                        <img class="result__sidebar__item--photo" src="./assets/images/video1.png" />
                        <button><img src="./assets/images/play-circle.svg" /></button>
                      </div> -->
                      <iframe width="125px" height="90px" src="https://www.youtube.com/embed/yhmXJvDlO8s"
                        frameborder="0" allowfullscreen></iframe>

                      <div class="result__sidebar__item--content">
                        <div class="result__sidebar__item--title">
                          <h3>Uromiogs Live 2023: Dr. Petros Grivas on Promising Future Treatments in Bladder Cancer
                          </h3>
                          <ul>
                            <li>GU Oncology Now</li>
                            <!-- <li>JP Astellas Pharma Inc</li> -->
                          </ul>
                        </div>
                        <div class="result__sidebar__item--info d-flex flex-column align-items-end">
                          <span class="result__sidebar__item--date">
                            Nov 9, 2023
                          </span>
                          <div class="result__sidebar__item--action">
                            <p class="m-0">Length-3:36</p>
                            <i class="bi bi-arrow-right-short"></i>
                          </div>
                        </div>
                      </div>
                    </div>
                    <!-- <div class="result__sidebar__item d-flex" data-id="video3">
                      <div class="result__sidebar__item--img">
                        <img class="result__sidebar__item--photo" src="./assets/images/video1.png" />
                        <button><img src="./assets/images/play-circle.svg" /></button>
                      </div>
                      <div class="result__sidebar__item--content">
                        <div class="result__sidebar__item--title">
                          <h3>title</h3>
                          <ul>
                            <li>Q2 2023 Earnings Call 4503.</li>
                            <li>JP Astellas Pharma Inc</li>
                          </ul>
                        </div>
                        <div class="result__sidebar__item--info d-flex flex-column align-items-end">
                          <span class="result__sidebar__item--date">
                            01 Nov 2023
                          </span>
                          <div class="result__sidebar__item--action">
                            <p class="m-0">Sent-28</p>
                            <i class="bi bi-arrow-right-short"></i>
                          </div>
                        </div>
                      </div>
                    </div> -->
                  </div>
                </div>
                <div class="result__info">
                  <div class="result__info__default" id="summary">
                    <h2 class="mb-3">Summary</h2>

                    <div class="result__summary__item">

                      <ul>
                        <li>
                          Dr. Petros Grivas discusses the evolving landscape of treatments for bladder cancer and upper
                          tract urothelial cancer (UTUC), highlighting both promising advancements and ongoing
                          challenges. Early data on Tar 200, with its 77% clinical complete response rate in non-muscle
                          invasive bladder cancer, showcases the potential of new treatments despite being in the early
                          stages. Dr. Grivas elaborates on several ongoing trials, including SUNED-1, SISE-2, SUNRISE-3,
                          and SUNRISE-4, aimed at exploring Tar 200's efficacy across different stages and settings of
                          bladder cancer. He emphasizes the significant progress made in metastatic urothelial carcinoma
                          treatment, notably with the EV-302 trial demonstrating substantial survival benefits with
                          Pembrolizumab and Enfortumab Vedotin. However, he also notes the barriers to broader
                          implementation, such as cost and access.
                        </li>
                        <li>Regarding UTUC, Dr. Grivas reflects on the challenges posed by the lack of definitive,
                          large-scale trial data, which complicates treatment standardization. He mentions the POUT
                          trial, providing strong evidence for the use of adjuvant chemotherapy in high-risk patients,
                          and discusses the ongoing debate and considerations around neoadjuvant versus adjuvant
                          chemotherapy, influenced by factors like potential loss of kidney function. Dr. Grivas
                          highlights the promise shown by emerging trials, such as ECOG-ACRIN 8141 and 8192, in
                          exploring the effectiveness of neoadjuvant chemotherapy and the need for more dedicated
                          research to advance treatment strategies</li>
                        <li>
                          Throughout, Dr. Grivas stresses the importance of personalized treatment approaches, informed
                          decision-making, and the critical role of clinical trials in navigating the complexities of
                          managing bladder cancer and UTUC. He combines optimism about the field's future with a
                          pragmatic view of the challenges ahead, underscoring the need for ongoing research to refine
                          and improve therapeutic protocols for these cancers.
                        </li>

                      </ul>

                    </div>
                    <div class="result__summary">
                      <div class="card__box">
                        <div class="result__summary__content">
                          <div class="result__summary__item">
                            <h4>Positive</h4>
                            <ul>
                              <li>Promising Developments and Early Results: Both discussions highlight significant
                                advancements and promising early results in bladder cancer and UTUC treatments,
                                fostering optimism.
                              </li>
                              <li>Ongoing Research and Future Trials: The focus on ongoing and future trials for new
                                therapeutic strategies shows a proactive research environment aimed at improving patient
                                outcomes.</li>
                              <li>
                                Personalized Treatment Approaches: The discussions reflect an understanding of the need
                                for personalized treatment decisions, crucial for tailoring therapy to individual
                                patient needs and improving prospects for patient outcomes and quality of life.
                              </li>

                            </ul>
                          </div>
                          <div class="result__summary__item">
                            <h4>Negative</h4>
                            <ul>
                              <li>
                                Early Stages and Limited Data: Challenges due to the early stages of treatments like Tar
                                200 and the lack of definitive, large-scale trial data for UTUC, highlighting
                                uncertainties about long-term efficacy and safety.
                              </li>
                              <li>
                                Cost, Accessibility, and Treatment Eligibility Concerns: Significant concerns about the
                                cost and accessibility of treatments, and difficulties in determining chemotherapy
                                eligibility due to potential kidney function loss, pose barriers to the widespread
                                adoption of these treatments.
                              </li>
                              <li>
                                Need for More Dedicated Trials: Both discussions underscore the pressing need for more
                                dedicated trials to overcome current research limitations and advance treatment
                                standards, pointing to a gap in the evidence base that needs addressing.
                              </li>

                            </ul>
                          </div>
                        </div>
                        <!-- <div class="result__summary__accordion">
                          <div class="result__summary__accordion--item">
                            <div class="result__summary__item--header">
                              <img src="./assets/images/arrow-right2.svg" />
                              Outlook from Earnings Call
                            </div>
                            <div class="result__summary__item--content">
                              Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has
                              been
                              the industry's standard dummy text ever since the 1500s, when an unknown printer took a
                              galley of
                              type and scrambled it to make a type specimen book. It has survived not only five
                              centuries, but
                              also the leap into electronic typesetting
                            </div>
                          </div>
                          <div class="result__summary__accordion--item">
                            <div class="result__summary__item--header">
                              <img src="./assets/images/arrow-right2.svg" />
                              Outlook from Earnings Call
                            </div>
                            <div class="result__summary__item--content">
                              Outlook from Earnings Call
                            </div>
                          </div>
                          <div class="result__summary__accordion--item">
                            <div class="result__summary__item--header">
                              <img src="./assets/images/arrow-right2.svg" />
                              Outlook from Earnings Call
                            </div>
                            <div class="result__summary__item--content">
                              Outlook from Earnings Call
                            </div>
                          </div>
                        </div> -->
                      </div>
                      <!-- <div class="card__box result__summary__info">
                        <h4>Astellas Pharma Inc</h4>
                        <a href="#">astellas.com</a>
                        <div class="result__summary__text">
                          <p>Astellas Pharma Inc is a drug manufacturing company that sells pharmaceutical products
                            across the
                            globe... <a href="#">Read More</a></p>

                        </div>
                        <div class="result__summary__table">
                          <div>
                            <span>Status</span>
                            <p>Public</p>
                          </div>
                          <div>
                            <span>MARKET CAP</span>
                            <p>$21.2B</p>
                          </div>
                          <div>
                            <span>MARKET CAP</span>
                            <p>$21.2B</p>
                          </div>
                          <div>
                            <span>MARKET CAP</span>
                            <p class="red__text">-28</p>
                          </div>
                          <div>
                            <span>MARKET CAP</span>
                            <p>$21.2B</p>
                          </div>
                        </div>
                        <button class="load__more button mx-auto">Show More</button>
                      </div> -->
                    </div>
                    <!-- <div class="result__research">
                      <h2 class="my-3">Research</h2>
                      <div class="card__box result__research__content">
                        <div class="result__summary__content">
                          <div class="result__summary__item">
                            <div>
                              <h4>Upgrades</h4>
                              <div class="result__summary__tag">
                                <img src="./assets/images/logo-blue.svg" />
                                <span>SMART SUMMARY</span>
                              </div>
                            </div>

                            <ul>
                              <li>Citi upgrades Astellas Pharma Inc to Buy based on fezolinetant's blockbuster potential
                              </li>
                              <li>IZERVAY received an approval from the US FDA and it was accepted for filing in Europe
                                in
                                August. (5)</li>
                            </ul>
                          </div>
                          <div class="result__summary__item">
                            <div>
                              <h4>Downgrades</h4>
                              <div class="result__summary__tag">
                                <img src="./assets/images/logo-blue.svg" />
                                <span>SMART SUMMARY</span>
                              </div>
                            </div>

                            <ul>
                              <li>Citi upgrades Astellas Pharma Inc to Buy based on fezolinetant's blockbuster potential
                              </li>
                              <li>IZERVAY received an approval from the US FDA and it was accepted for filing in Europe
                                in
                                August. <span>(5)</span></li>
                              <li>IZERVAY received an approval from the US FDA and it was accepted for filing in Europe
                                in
                                August. (5)</li>
                              <li>IZERVAY received an approval from the US FDA and it was accepted for filing in Europe
                                in
                                August. (5)</li>
                              <li>IZERVAY received an approval from the US FDA and it was accepted for filing in Europe
                                in
                                August. (5)</li>
                              <li>IZERVAY received an approval from the US FDA and it was accepted for filing in Europe
                                in
                                August. (5)</li>
                            </ul>
                          </div>
                        </div>
                        <div class="result__summary__accordion">
                          <div class="result__summary__accordion--item">
                            <div class="result__summary__item--header">
                              <img src="./assets/images/arrow-right2.svg" />
                              Outlook from Earnings Call
                            </div>
                            <div class="result__summary__item--content">
                              Lorem Ipsum is simply dummy text of the printing and typesetting industry. Lorem Ipsum has
                              been
                              the industry's standard dummy text ever since the 1500s, when an unknown printer took a
                              galley of
                              type and scrambled it to make a type specimen book. It has survived not only five
                              centuries, but
                              also the leap into electronic typesetting
                            </div>
                          </div>
                          <div class="result__summary__accordion--item">
                            <div class="result__summary__item--header">
                              <img src="./assets/images/arrow-right2.svg" />
                              Outlook from Earnings Call
                            </div>
                            <div class="result__summary__item--content">
                              Outlook from Earnings Call
                            </div>
                          </div>
                          <div class="result__summary__accordion--item">
                            <div class="result__summary__item--header">
                              <img src="./assets/images/arrow-right2.svg" />
                              Outlook from Earnings Call
                            </div>
                            <div class="result__summary__item--content">
                              Outlook from Earnings Call
                            </div>
                          </div>
                        </div>
                      </div>
                    </div> -->
                  </div>
                  <div class="result__info__video" id="video1">
                    <div class="result__filter">
                      <div class="result__filter__btn">
                        <button class="result__filter__button">
                          Keywords
                        </button>
                        <button class="result__filter__button active">
                          Search in Video
                        </button>
                      </div>

                      <div class="result__filter__search">
                        <i class="bi bi-search"></i>
                        <input type="text" id="default-search" />
                        <div class="result__search__right">
                          <span>Clear</span>
                        </div>
                      </div>
                      <!-- <div class="result__filter__box">
                        Maybe you could talk a little bit more about the typical side effects, specifically hot flashes most relevant to this conversation.
                      </div> -->
                      <!-- <div class="result__filter__box">
                        Any theories on what than 20% doesn’t have any side effects?
                        <div class="result__filter__action">
                          <button>
                            <i class="bi bi-bounding-box-circles"></i> Copy Link
                          </button>
                          <button>
                            <i class="bi bi-three-dots"></i> Add to Note
                          </button>
                        </div>
                      </div> -->
                    </div>
                    <div class="card__box">
                      <div class="card__box__header d-flex align-items-center">
                        <div class="card__box__title d-flex align-items-center">
                          <img src="./assets/images/logo-black.png" />
                          <h2 class="ms-1">KOL Insights</h2>
                        </div>
                      </div>
                      <div class="result__info__detail">
                        <h1 class="m-0">Uromiogs Live 2023: Dr. Petros Grivas on Promising Future Treatments in Bladder
                          Cancer</h1>
                        <div class="result__info__doctor">
                          <span>KOL Info</span>
                          <span>GU Oncology Now</span>
                        </div>
                        <div class="result__info__doctor">
                          <span> Date </span>
                          <span>Nov 9, 2023</span>
                        </div>
                        <div class="result__info__like">
                          <button>
                            <i class="bi bi-hand-thumbs-up"></i>
                          </button>
                          <button>
                            <i class="bi bi-hand-thumbs-down"></i>
                          </button>
                        </div>
                        <div class="result__info__summary">
                          <h5>Summary</h5>
                          <ul>
                            <li>
                              Tar 200 in Non-Muscle Invasive Bladder Cancer: Early data on Tar 200, delivering
                              gemcitabine intravesically, is promising with a 77% clinical complete response rate in a
                              study involving 30 patients. Though in its early stages, the potential of Tar 200 is
                              noted.
                            </li>
                            <li>
                              Ongoing Trials with Tar 200: Four trials are mentioned:
                              • SUNED-1: Tar 200 monotherapy in BCG-unresponsive disease.
                              • SISE-2: Muscle-invasive bladder cancer, combining Tar 200 with a checkpoint inhibitor
                              versus chemoradiation.
                              • SUNRISE-3: In BCG-naive space.
                              • SUNRISE-4: In neoadjuvant therapy for muscle-invasive bladder cancer, targeting PD-L1
                              ineligible patients.
                              The Tar 200 program is described as exciting and promising, though not yet
                              practice-changing
                            </li>
                            <li>
                              Metastatic Urothelial Carcinoma: Significant progress is noted, especially with the EV-302
                              trial showing substantial improvements in progression-free survival (PFS) and overall
                              survival (OS) when comparing Pembrolizumab and Enfortumab Vedotin (EV) against
                              chemotherapy. The trial indicated a significant survival benefit, making Pembrolizumab the
                              new standard of care for eligible patients. However, the cost and access to this treatment
                              raise concerns for broader implementation.
                            </li>
                            <li>
                              Additional Considerations:
                              • The discussion touches on managing patients previously treated with checkpoint
                              inhibitors, dose management, and the importance of ongoing trials in establishing
                              appropriate control arms.
                              • For places where Pembrolizumab isn't covered, Avelumab emerges as an alternative, with
                              the JAVELIN Bladder 100 paradigm being practice-changing for patients unfit for
                              platinum-based therapy.
                              • Erdafitinib versus chemotherapy trials are mentioned as important and worth reviewing
                              for their impact on patient longevity and quality of life.
                            </li>
                          </ul>
                        </div>

                        <div class="result__info__summary">
                          <h5>Sentiment Analysis</h5>
                          <h5>Positive</h5>
                          <ul>
                            <li>
                              Promising Early Results: The transcript begins on a positive note, highlighting the
                              promising results of Tar 200 in treating non-muscle invasive bladder cancer, with a 77%
                              clinical complete response rate in early trials.
                            </li>
                            <li>
                              Exciting Ongoing Trials: The discussion of four ongoing trials with Tar 200 and their
                              potential to change practice in the future conveys a strong sense of optimism about the
                              progress in bladder cancer treatment.
                            </li>
                            <li>
                              Significant Advancements in Metastatic Urothelial Carcinoma: The success of the EV-302
                              trial, showing substantial improvements in survival rates with Pembrolizumab and
                              Enfortumab Vedotin, represents a major advancement in the treatment of metastatic
                              urothelial carcinoma.
                            </li>
                            <li>
                              New Standard of Care: Pembrolizumab is highlighted as the new standard of care for
                              eligible patients, indicating a transformative improvement in treatment.
                            </li>
                            <li>
                              Variety of Options for Different Patient Groups: The mention of alternatives like Avelumab
                              and Erdafitinib for specific patient groups suggests a growing array of treatment options,
                              improving prospects for patient outcomes and quality of life
                            </li>
                          </ul>
                        </div>
                        <div class="result__info__summary">
                          <h5>Negative</h5>
                          <ul>
                            <li>
                              Early Stages and Limited Data: Despite the promising start, the transcript acknowledges
                              that it's early days for Tar 200, with only a small patient sample and short follow-up,
                              indicating uncertainty about long-term efficacy and safety.
                            </li>
                            <li>
                              Cost and Accessibility Concerns: The significant concern about the cost and accessibility
                              of Pembrolizumab and Enfortumab Vedotin for patients in different countries points to a
                              significant barrier in the widespread adoption of these treatments.
                            </li>
                            <li>
                              Management of Previous Treatments: The challenges in managing patients with prior
                              checkpoint inhibitor exposure and the need for dose management and therapy modifications
                              highlight the complexity of treatment pathways and potential hurdles in achieving optimal
                              outcomes.
                            </li>
                            <li>
                              Ongoing Trials and Future Uncertainties: While the transcript mentions ongoing trials,
                              there's an implicit acknowledgment of uncertainties about their outcomes and the future
                              standard of care in bladder cancer treatment.
                            </li>
                            <li>
                              Inequity in Treatment Access: The differentiation of treatment options based on the
                              reimbursement policies of different countries hints at inequity in access to the most
                              advanced treatments, potentially affecting patient outcomes based on geographic location.
                            </li>
                          </ul>
                        </div>
                        <!-- <div class="result__info__content d-flex">
                          <div class="result__info__card">
                            <h5>TABLE OF CONTENTS</h5>
                            <ul>
                              <li>
                                Lorem ipsum dolor sit amet consectetur. Amet placerat convallis sed mattis morbi purus. Quis a ullamcorper sollicitudin ut ultricies vulputate amet ornare. 
                              </li>
                              <li>
                                Lorem ipsum dolor sit amet consectetur. Amet placerat convallis sed mattis morbi purus. 
                              </li>
                              <li>
                                Lorem ipsum dolor sit amet consectetur. Amet placerat convallis sed mattis morbi purus. 
                              </li>
                            </ul>
                          </div>
                          <div class="result__info__card result__info__action">
                            <p>Lorem ipsum dolor sit amet consectetur. Amet placerat convallis sed mattis mor.</p>
                            <div>
                              <button class="button">Expert Bio</button>
                              <button class="button">Employment History</button>
                            </div>
                          </div>
                        </div> -->
                      </div>
                    </div>
                  </div>
                  <div class="result__info__video" id="video2">

                    <div class="card__box">
                      <div class="card__box__header d-flex align-items-center">
                        <div class="card__box__title d-flex align-items-center">
                          <img src="./assets/images/logo-black.png" />
                          <h2 class="ms-1">KOL Insights</h2>
                        </div>
                      </div>
                      <div class="result__info__detail">
                        <h1 class="m-0">Uromiogs Live 2023: Dr. Petros Grivas on Promising Future Treatments in Bladder
                          Cancer</h1>
                        <div class="result__info__doctor">
                          <span>KOL Info</span>
                          <span>GU Oncology Now</span>
                        </div>
                        <div class="result__info__doctor">
                          <span> Date </span>
                          <span>Nov 9, 2023</span>
                        </div>
                        <div class="result__info__like">
                          <button>
                            <i class="bi bi-hand-thumbs-up"></i>
                          </button>
                          <button>
                            <i class="bi bi-hand-thumbs-down"></i>
                          </button>
                        </div>
                        <div class="result__info__summary">
                          <h5>Summary</h5>
                          <ul>
                            <li>
                              Lack of Definitive Data for UTUC: Unlike bladder cancer, there is a scarcity of definitive
                              phase 3 trial data for upper tract urothelial cancer due to its lower incidence. This
                              makes accruing patients for such trials challenging.
                            </li>
                            <li>
                              POUT Trial Insights: The POUT trial provides level one evidence supporting the use of
                              adjuvant chemotherapy in patients with high-risk upper tract urothelial carcinoma. It
                              showed a significant improvement in disease-free survival for patients treated with
                              adjuvant platinum-based chemotherapy.
                            </li>
                            <li>
                              Challenges with Neoadjuvant Chemotherapy: Due to the rarity of the disease and lack of
                              definitive large-scale trial data, there's ongoing debate about the role of neoadjuvant
                              chemotherapy. However, phase 2 trials and retrospective studies suggest benefits, such as
                              pathologic downstaging, which could be associated with improved long-term outcomes.
                            </li>
                            <li>
                              Considerations for Chemotherapy: The decision to use neoadjuvant or adjuvant chemotherapy
                              is influenced by several factors, including the patient's ability to receive
                              cisplatin-based regimens due to potential loss of kidney function. For those ineligible
                              for cisplatin, carboplatin is considered, though data is less definitive.
                            </li>
                            <li>
                              Efficacy of New Treatment Strategies: Emerging trials, such as the ECOG-ACRIN 8141 and
                              others, explore the effectiveness of neoadjuvant chemotherapy, showing promising but
                              limited pathologic complete response rates. These efforts underscore the need for more
                              dedicated trials in this setting.
                            </li>
                            <li>
                              Current Clinical Trials and Future Directions: The ECOG-ACRIN 8192 trial is highlighted as
                              an important ongoing study investigating the efficacy of neoadjuvant chemotherapy with or
                              without immunotherapy in UTUC. This trial is crucial for developing new therapeutic
                              strategies and improving patient outcomes.
                            </li>
                            <li>
                              Subgroup Analysis and Treatment Eligibility: The discussion also touches on the use of
                              adjuvant nivolumab, acknowledging the limitations of current data, particularly for
                              patients with upper tract disease. The importance of clinical trials, informed
                              decision-making, and personalized treatment approaches based on patient eligibility and
                              risk factors is emphasized.
                            </li>
                          </ul>
                        </div>

                        <div class="result__info__summary">
                          <h5>Sentiment Analysis</h5>
                          <h5>Positive</h5>
                          <ul>
                            <li>
                              Evidence-Based Support for Adjuvant Therapy: The mention of the POUT trial provides
                              strong, evidence-based support for the use of adjuvant chemotherapy in patients with
                              high-risk UTUC, showcasing significant improvements in disease-free survival. This
                              represents a clear advancement in the treatment landscape.
                            </li>
                            <li>
                              Ongoing Research and Trials: The discussion highlights ongoing and future trials, such as
                              the ECOG-ACRIN 8192, which are exploring new therapeutic strategies, including the
                              combination of chemotherapy with immunotherapy. This indicates a proactive research
                              environment aimed at improving patient outcome
                            </li>
                            <li>
                              Advancements in Treatment Strategies: The conversation acknowledges the development of new
                              treatment strategies and the potential benefits of neoadjuvant chemotherapy, evidenced by
                              phase 2 trials and retrospective studies suggesting pathologic downstaging associated with
                              improved outcomes.
                            </li>
                            <li>
                              Personalized Treatment Approaches: The transcript reflects an understanding of the need
                              for personalized treatment decisions, especially in light of the challenges with
                              chemotherapy eligibility due to factors like kidney function, which is crucial for
                              tailoring therapy to individual patient needs.
                            </li>

                          </ul>
                        </div>
                        <div class="result__info__summary">
                          <h5>Negative</h5>
                          <ul>
                            <li>
                              Lack of Definitive Data: A significant challenge highlighted is the lack of definitive,
                              large-scale trial data for UTUC, which complicates establishing standardized treatment
                              protocols and may hinder the optimization of patient care.
                            </li>
                            <li>
                              Challenges in Treatment Eligibility: The discussion underscores the difficulty in
                              determining patients' eligibility for certain chemotherapy regimens, particularly
                              cisplatin, due to potential kidney function loss. This can limit treatment options and
                              affect outcomes.
                            </li>
                            <li>
                              Underpowered Studies and Uncertainty: The mention of underpowered studies, particularly in
                              the context of adjuvant nivolumab and its efficacy in UTUC compared to bladder cancer,
                              introduces a sense of uncertainty regarding the interpretation of existing data and its
                              application in clinical practice.
                            </li>
                            <li>
                              Need for More Dedicated Trials: The transcript conveys a pressing need for more dedicated
                              trials specifically designed for UTUC to overcome the limitations of current research.
                              This highlights a gap in the evidence base that needs to be addressed to advance treatment
                              standards.
                            </li>

                          </ul>
                        </div>
                        <!-- <div class="result__info__content d-flex">
                          <div class="result__info__card">
                            <h5>TABLE OF CONTENTS</h5>
                            <ul>
                              <li>
                                Lorem ipsum dolor sit amet consectetur. Amet placerat convallis sed mattis morbi purus. Quis a ullamcorper sollicitudin ut ultricies vulputate amet ornare. 
                              </li>
                              <li>
                                Lorem ipsum dolor sit amet consectetur. Amet placerat convallis sed mattis morbi purus. 
                              </li>
                              <li>
                                Lorem ipsum dolor sit amet consectetur. Amet placerat convallis sed mattis morbi purus. 
                              </li>
                            </ul>
                          </div>
                          <div class="result__info__card result__info__action">
                            <p>Lorem ipsum dolor sit amet consectetur. Amet placerat convallis sed mattis mor.</p>
                            <div>
                              <button class="button">Expert Bio</button>
                              <button class="button">Employment History</button>
                            </div>
                          </div>
                        </div> -->
                      </div>
                    </div>

                  </div>
                </div>
              </div>
            </div>
          </div>

        </main>
      </div>
    </div>

    <!-- <div id="fadein" class="position-fixed top-0 start-0 w-100 h-100 bg-white"
    style="animation: fadeinall 1s normal 0.3s both;"></div> -->

    <script src="https://code.jquery.com/jquery-3.7.1.min.js" crossorigin="anonymous"></script>
    <script src="https://cdn.jsdelivr.net/npm/bootstrap@5.3.2/dist/js/bootstrap.bundle.min.js"
      crossorigin="anonymous"></script>
    <script src="https://cdn.ckeditor.com/ckeditor5/41.1.0/classic/ckeditor.js"></script>
    <script src="https://cdn.jsdelivr.net/npm/apexcharts"></script>
    <script type="text/javascript" src="https://www.gstatic.com/charts/loader.js"></script>
    <script src="./assets/js/main.js"></script>


    <script>
      $(document).ready(function () {
        // Define the JavaScript object
        var mykol = [
          { Firstname: "Matt", LastName: "Campbell", Institution: "MDACC" },
          { Firstname: "Arlene", LastName: "Siefker-Radtke", Institution: "MDACC" },
          { Firstname: "Neeraj", LastName: "Agarwal", Institution: "Huntsman Cancer Inst" },
          { Firstname: "Tanya", LastName: "Dorff", Institution: "USC" },
          { Firstname: "Alexandra", LastName: "Drakaki", Institution: "UCLA" },
          { Firstname: "Thomas", LastName: "Flaig", Institution: "U of Colorado" },
          { Firstname: "Terence", LastName: "Friedlander", Institution: "UCSF" },
          { Firstname: "Petros", LastName: "Grivas", Institution: "University of Washington" },
          { Firstname: "Primo", LastName: "Lara", Institution: "UC Davis" },
          { Firstname: "Monty", LastName: "Pal", Institution: "COH" },
          { Firstname: "David", LastName: "Quinn", Institution: "USC" },
          { Firstname: "Parminder", LastName: "Singh", Institution: "U of AZ" },
          { Firstname: "Sandy", LastName: "Srinivas", Institution: "Stanford" },
          { Firstname: "Nick", LastName: "Vogelzang", Institution: "Comp Cancer Center Nevada" },
          { Firstname: "Elisabeth", LastName: "Heath", Institution: "Karmanos Cancer Institute" },
          { Firstname: "Alicia", LastName: "Morgans", Institution: "Northwestern University" },
          { Firstname: "Peter", LastName: "O'Donnell", Institution: "University of Chicago" },
          { Firstname: "Andrea", LastName: "Apolo", Institution: "NCI" },
          { Firstname: "Arjun", LastName: "Balar", Institution: "NYU" },
          { Firstname: "Joaquim", LastName: "Bellmunt", Institution: "Beth Israel" },
          { Firstname: "Robert", LastName: "Dreicer", Institution: "UVA" },
          { Firstname: "Matt", LastName: "Galsky", Institution: "Mount Sinai" },
          { Firstname: "Daniel", LastName: "George", Institution: "Duke" },
          { Firstname: "Shilpa", LastName: "Gupta", Institution: "Cleveland Clinic" },
          { Firstname: "Noah", LastName: "Hahn", Institution: "Johns Hopkins University" },
          { Firstname: "Jean", LastName: "Hoffman-Censits", Institution: "Johns Hopkins" },
          { Firstname: "Christopher", LastName: "Hoimes", Institution: "Duke" },
          { Firstname: "Ronac", LastName: "Mamtani", Institution: "PENN" },
          { Firstname: "Brad", LastName: "McGregor", Institution: "Dana Farber" },
          { Firstname: "Matt", LastName: "Milowsky", Institution: "UNC" },
          { Firstname: "Dan", LastName: "Petrylak", Institution: "Yale" },
          { Firstname: "Betsy", LastName: "Plimack", Institution: "Fox Chase" },
          { Firstname: "Jonathan", LastName: "Rosenberg", Institution: "MSKCC" },
          { Firstname: "Guru", LastName: "Sonpavde", Institution: "Dana Farber" },
          { Firstname: "Scott", LastName: "Tagawa", Institution: "Cornell" },
          { Firstname: "Tian", LastName: "Zhang", Institution: "Duke" },
          { Firstname: "Ajjai", LastName: "Alva", Institution: "Univeristy of Michigan" },
          { Firstname: "Vivek", LastName: "Arora", Institution: "Washington University" },
          { Firstname: "Walter", LastName: "Stadler", Institution: "University of Chicago" },
          { Firstname: "Saby", LastName: "George", Institution: "Roswell Park" }
        ];
        // Function to populate the table with dynamic data
        // function populateTable() {
        //   var tableBody = $("table tbody");

        //   // Clear existing table rows
        //   tableBody.empty();

        //   // Iterate over the object and create table rows
        //   $.each(mykol, function (index, entry) {
        //     var row = $("<tr></tr>");
        //     row.append("<td>" + entry.Firstname + "</td>");
        //     row.append("<td>" + entry.LastName + "</td>");
        //     row.append("<td>" + entry.Institution + "</td>");
        //     tableBody.append(row);
        //   });
        // }

        // // Call the function to populate the table initially
        // populateTable();

        // table dynamic  code start

        var itemsToShow = 5; // Number of items to show initially
        var itemsLoaded = 0;

        // Function to add rows to the table
        function addRows(start, end) {
          for (var i = start; i < end; i++) {
            var row = $('<tr>');
            row.append($('<td>').text(mykol[i].Firstname));
            row.append($('<td>').text(mykol[i].LastName));
            row.append($('<td>').text(mykol[i].Institution));
            $('#kol_table tbody').append(row);
          }
          itemsLoaded = end;
        }

        // Load initial rows
        addRows(0, itemsToShow);

        // Load more button click event
        $('#table_kol_load_more').click(function () {
          var remainingItems = mykol.length - itemsLoaded;
          var nextItems = Math.min(remainingItems, itemsToShow);
          addRows(itemsLoaded, itemsLoaded + nextItems);

          if (itemsLoaded === mykol.length) {
            $('#table_kol_load_more').hide();
          }
        });

        // table code end

        $(".user_selected").hide();

        $(document).on("click", ".user_name_menu", function () {

          const dataId = $(this).attr("data-id");
          if (dataId) {
            if ($(this).hasClass("active")) {
              $(this).removeClass("active");
              $("#" + dataId).hide();
              $(".dashboard__content").show();
            } else {
              $(".user_name_menu").removeClass("active");
              $(this).addClass("active");
              $(".dashboard__content").hide();
              $(".user_selected").hide();
              $("#" + dataId).show();
            }
          }

        });
        // $.each(mykol, function (index, person) {
        //   // Create a div element for each person
        //   var div = $("<div>").addClass("dashboard__sidebar__list--item");

        //   // Create an anchor element with href="#" inside the div
        //   var anchor = $("<a>").attr("href", "#").appendTo(div);

        //   // Create an h4 element with the person's name and append it to the anchor
        //   $("<h4>").addClass("user_name_menu").attr("data-id", `user_name`).text(person.Firstname + " " + person.LastName).appendTo(anchor);

        //   // Create a p element with the person's institution and append it to the anchor
        //   $("<p>").addClass("institution m-0").text(person.Institution).appendTo(anchor);

        //   // Append the div to the container where you want to display the list
        //   div.appendTo(".dashboard__sidebar__list"); // Change ".container" to your actual container selector
        // });


        function displayItems(startIndex, count) {
          var end = Math.min(startIndex + count, mykol.length);
          for (var i = startIndex; i < end; i++) {
            var person = mykol[i];
            var div = $("<div>").addClass("dashboard__sidebar__list--item");
            var anchor = $("<a>").attr("href", "#").appendTo(div);
            $("<h4>").addClass("user_name_menu").attr("data-id", `user_name`).text(person.Firstname + " " + person.LastName).appendTo(anchor);
            $("<p>").addClass("institution m-0").text(person.Institution).appendTo(anchor);
            div.appendTo(".dashboard__sidebar__list");
          }
        }

        // Initial display
        var itemsToShow = 8;
        displayItems(0, itemsToShow);

        // Load more button click event
        var startIndex = itemsToShow;
        var itemsPerLoad = 8; // Change this to adjust the number of items loaded per click
        $("#load_more_List_kol_user").on("click", function () {
          displayItems(startIndex, itemsPerLoad);
          startIndex += itemsPerLoad;
          // Hide the button if all items are loaded
          if (startIndex >= mykol.length) {
            $("#load_more_List_kol_user").hide();
          }
        });
      });

    </script>

</body>

</html>